Specific drugs (catumaxomab and edrecolomab) targeting EpCAM have been developed, which can significantly reduce the size of tumor used alone or in combination with standard treatment, demonstrating the potential of such targeting strategies (26,27). The gene discussed is EPCAM; the disease is neoplasm.